期刊文献+

医学影像学评估甲状腺相关性眼病活动度的价值 被引量:4

The value of imaging in evaluating disease activity of thyroid associated ophthalmopathy
原文传递
导出
摘要 甲状腺相关性眼病(thyroid associated ophthalmopathy,TAO)是一种器官特异性自身免疫性疾病,其治疗方案的确定及疗效观察依赖于临床活动度的评估。临床多以临床活动度评分(clinical activity score,CAS)作为TAO活动度的评价标准,但有一定的局限性。CT成像眼外肌形态学的定量分析(眼外肌总横截面积/眼眶面积比值)结果与CAS评分呈正相关;通过眼外肌T2 mapping MRI定量分析提示眼外肌T2值与TAO免疫抑制疗效密切相关,有助于评估TAO免疫抑制疗效;^(99m)Tc-DTPA眼眶SPECT/CT采用图像融合技术,一次显像可获得功能信息与解剖信息,可作为CAS的有效补充。现代医学影像学特别是功能影像学对TAO活动度的评估具有较大的应用价值。 Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease. Clinical activity score (CAS) is often used for the assessment of disease activity in TAO, but it has certain limitations. The morphology of extraocular muscles(orbital extraocular muscle coronal area/total orbit coronal area ratio, OM/TOA ratio)in compated tomography (CT) imaging were positively cor- related with CAS. Quantitative analysis of T2 mapping magnetic resonance imaging (MRI) of extraocular muscle indicated that T2 value of extraocular muscle was closely related to the effect of immunosuppression, which was helpful for evaluating the effect of immunosup- pression treatment. SPECT/CT using ~I'c-DTPA for the assessment of disease activity in TAO, which can obtain functional information and anatomical information in one imaging. It can be used as an effective complement to CAS. Modem medical imaging, especially functional imaging, has great application value in evaluating disease activity of TAO.
作者 李眉 燕飞 LI Mei;YAN Fei(Department of Nuclear Medicine;Department of Radiology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)
出处 《眼科》 CAS CSCD 2018年第5期321-324,共4页 Ophthalmology in China
关键词 甲状腺相关性眼病 临床活动度评分 计算机断层扫描 磁共振成像 thyroid-associated ophthalmopathy clinical activity score computed tomography magnetic resonance imaging
  • 相关文献

参考文献7

二级参考文献29

  • 1段炼,李险峰,陆克义,张承刚,胡光,刘建中,李思进.^(99)Tc^m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用[J].中华眼科杂志,2006(12):1068-1072. 被引量:18
  • 2Smith TJ. Pathogenesis of Graves" orbitopathy:a 2010 update. J Endocrinol Invest, 2010, 33: 414-421.
  • 3Salvi M, Vannucchi G, Campi L, et al. Treatment of Graves" dis- ease and associated ophthalmopathy with the auti-CD20 mouoclon- al antibody rituximab: an open study. Eur J Endocrinol, 2007, 156: 33-40.
  • 4Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol, 2008, 158: 273-285.
  • 5Garrity JA, Bahn RS. Pathogenesis of Graves'ophthalmopathy: im- plications for prediction, prevention and treatment. Am J Ophthal- mol, 2006, 142: 147-153.
  • 6Perros P, Krassas GE. Graves orbitopathy: A perspective. Nat Rev Endocrinol, 2009, 5: 312-318.
  • 7Pasquali D, Notaro A, Bonarolorta G, et al. Somatostatin receptor genes are expressed in lymphocytes from retro orbital tissues in Graves' disease. J Clin Endocrinol Metab, 2002, 87: 5125-5129.
  • 8Khanna G, Bushnell D, O'Dorisio MS. Utility of radiolabeled so- matostatin receptor analogues for staging/restaging and treatment of somatostatiu receptor positive pediatric tumors. Oncologist, 2008, 13: 382-389.
  • 9Postema PTE, Krenning EP, Wijingaarde R, et al. l 11-In DT- PA-D-Phel octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?. J Clin En- docrinol Metab, 1994, 79: 1845-1851.
  • 10Laszlo G, Andras L, Zsolt SF, et al. Imaging of disease activity in Graves'orbitopathy with different methods: comparison of 9'rTC- DTPA and 99fc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun, 2005, 26: 407-414.

共引文献55

同被引文献32

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部